RxSight announced a leadership transition that will take effect July 20, 2026, with commercial executive Aziz Mottiwala appointed President and Chief Executive Officer, succeeding Ron Kurtz, MD, who will continue with the company as Chief Medical Officer.

As part of the transition, Dr. Kurtz will step down from the company's board of directors, and Mr. Mottiwala will join the board.

Mr. Mottiwala brings more than a decade of leadership experience in ophthalmology and biopharmaceutical commercialization. Most recently, he served as chief commercial officer at Tarsus Pharmaceuticals. He previously held the same role at Opiant Pharmaceuticals and spent more than 10 years at Allergan, where he held senior leadership positions across its eye care franchise and broader commercial organization.

"I am excited and honored to join RxSight at such a critical time for the company," Mr. Mottiwala said. "RxSight has created a unique and differentiated platform with significant opportunity ahead. Adjustability has brought a new level of accuracy and customization to modern cataract surgery that is still in the early stages of market adoption."

"We are excited to welcome Aziz to RxSight and believe his deep commercial and operational experience in eye care makes him exceptionally well suited to lead the company into its next chapter of value creation," said Andy Corley, chairman of the RxSight board of directors. "On behalf of the Board, I want to express our sincere appreciation to Ron for his vision and leadership in establishing adjustability in the ophthalmic marketplace, and for his continued commitment to advancing our technology and clinical value as Chief Medical Officer."

The leadership transition comes just a week after RxSight entered into a non-exclusive collaboration with Alcon to jointly develop adjustable presbyopia-correcting IOLs (PCIOLs). In the deal, which aims to combine each company's technologies to expand customization options for patients undergoing cataract surgery, RxSight will receive a $60 million upfront payment to initiate development activities. The company is eligible to receive up to an additional $140 million upon achievement of specified development and regulatory milestones.